Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00513617 |
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited genetic disease that can cause intense pain episodes. This study will evaluate the effectiveness of the nutritional supplement arginine at improving blood cell function and disease symptoms in people with SCD.
Condition | Intervention | Phase |
---|---|---|
Anemia, Sickle Cell |
Drug: Arginine Other: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Arginine Supplementation in Sickle Cell Anemia: Physiological and Prophylactic Effects |
Estimated Enrollment: | 96 |
Study Start Date: | June 2004 |
Study Completion Date: | January 2008 |
Primary Completion Date: | September 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Low Dose: Active Comparator
0.05 g/kg/day
|
Drug: Arginine
Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
|
High Dose: Active Comparator
0.10 g/kg/day
|
Drug: Arginine
Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
|
Placebo: Placebo Comparator |
Other: Placebo
Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
|
SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and intense episodes of pain that are called "sickle cell crises." SCD is caused by an abnormal type of hemoglobin, which is a protein inside red blood cells that carries oxygen. In people with SCD, the abnormal hemoglobin distorts the shape of the red blood cells. This causes the red blood cells to clump together, decreasing blood flow and oxygen delivery to the body's tissues. The reduced levels of oxygen can lead to sickle cell crises and tissue damage. Hemolysis, the destruction of red blood cells, is also a hallmark of SCD. During hemolysis, hemoglobin is released into the bloodstream, where it removes nitric oxide (NO), a natural chemical in the body that expands blood vessels. Arginase, another protein released during hemolysis, removes arginine from the bloodstream, which can also lead to decreased NO levels. The lack of NO constricts blood vessels, further contributing to painful sickle cell crises. Arginine supplementation may increase healthy hemoglobin and NO production and, in turn, prevent or reduce sickle cell crises. The purpose of this study is to evaluate the effectiveness of arginine at increasing NO levels, improving red blood cell function, and reducing hospitalizations and pain medication use in people with SCD.
This study will enroll children and adults with SCD. Participants will be randomly assigned to receive twice daily doses of either a low dose of arginine, a high dose of arginine, or placebo for 12 weeks. Study visits will occur at baseline, three times during Month 1, and Weeks 8, 12, 14, and 16. Each study visit will include an echocardiogram to measure heart activity, blood collection, and a medical history review to identify adverse events, pain medication usage, headaches, emergency department visits, and hospitalizations.
Ages Eligible for Study: | 5 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
University of California - San Francisco | |
San Francisco, California, United States, 94143 | |
Children's Hospital of Oakland and Research Institute | |
Oakland, California, United States, 94609 | |
United States, Colorado | |
University of Colorado at Denver and Health Sciences Center--Sickle Cell Treatment and Research Center | |
Denver, Colorado, United States, 80262 | |
United States, Kentucky | |
Kosair Children's Hospital | |
Louisville, Kentucky, United States, 40202 | |
United States, Massachusetts | |
Boston Medical Center | |
Boston, Massachusetts, United States, 02118 | |
United States, Mississippi | |
University of Mississippi Medical Center (Pediatric) | |
Jackson, Mississippi, United States, 39215 | |
University of Mississippi Medical Center (Adult) | |
Jackson, Mississippi, United States, 39215 | |
United States, New York | |
Montefiore Medical Center | |
Bronx, New York, United States, 10463 | |
Children's Hospital of Montefiore | |
Bronx, New York, United States, 10467 | |
United States, North Carolina | |
University of North Carolina at Chapel Hill | |
Chapel Hill, North Carolina, United States, 27599 | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Oklahoma | |
Children's Hospital of Oklahoma | |
Oklahoma City, Oklahoma, United States, 73104 | |
United States, Pennsylvania | |
Children's Hospital of Philadelphia | |
Philadelphia, Pennsylvania, United States, 19444 | |
Thomas Jefferson University | |
Philadelphia, Pennsylvania, United States, 19107 | |
St. Christopher's Children's Research Hospital | |
Philadelphia, Pennsylvania, United States, 19134 | |
United States, Tennessee | |
St. Jude Children's Research Hospital | |
Memphis, Tennessee, United States, 38105 | |
United States, Texas | |
Children's Medical Center of Dallas | |
Dallas, Texas, United States, 75390 |
Principal Investigator: | Lillian McMahon, MD | Boston Medical Center |
Principal Investigator: | Rathi Iyer, MD | University of Mississippi Medical Center (Pediatric) |
Principal Investigator: | Carolyn Bigelow, MD | University of Mississippi Medical Center (Adult) |
Principal Investigator: | Lennette Benjamin, MD | Montefiore Medical Center |
Principal Investigator: | Mary Fabry, MD | Albert Einstein College of Medicine of Yeshiva University |
Principal Investigator: | Thomas Moulton, MD | Children's Hospital of Montefiore |
Principal Investigator: | Kim Smith-Whitley, MD | Children's Hospital of Philadelphia |
Principal Investigator: | Laura DeCastro, MD | Duke University |
Principal Investigator: | Kenneth Ataga, MD | The University of North Carolina, Chapel Hill |
Principal Investigator: | Samir K. Ballas, MD | Thomas Jefferson University |
Principal Investigator: | Sal Bertalone, MD | Norton Healthcare |
Principal Investigator: | Carlton Dampier, MD | St. Christopher's Childrens Hospital |
Principal Investigator: | William Mentzer, MD | University of California, San Francisco |
Principal Investigator: | Winfred Wang, MD | St. Jude's Childrens Research Hospital |
Principal Investigator: | Ulrike Reiss, MD | St. Jude Children's Research Hospital |
Principal Investigator: | Cynthia Rutherford, MD | Children's Medical Center of Dallas |
Principal Investigator: | Kathryn Hassell, MD | University of Colorado at Denver and Health Sciences Center |
Principal Investigator: | Joan Parkhurst Cain, MD | Children's Hospital of Oklahoma |
Responsible Party: | Childrens Hospital of Oakland and Research Institute ( Lori Styles/Principal Investigator ) |
Study ID Numbers: | 485, U54 HL070587-04 |
Study First Received: | August 6, 2007 |
Last Updated: | January 18, 2008 |
ClinicalTrials.gov Identifier: | NCT00513617 |
Health Authority: | United States: Food and Drug Administration |
Sickle Cell Disease Anemia Nitric Oxide Vaso Occlusive Events Arginine Supplementation |
Nitric Oxide Anemia, Hemolytic, Congenital Genetic Diseases, Inborn Hematologic Diseases Hemoglobinopathies |
Anemia Anemia, Hemolytic Hemoglobinopathy Anemia, Sickle Cell Sickle cell anemia |